The overall safety profile of pola added to R/G-CHP, including serious AEs, grade 3–4 AEs and events of peripheral neuropathy [45], is manageable and largely similar to treatment with R/G-CHOP, with vincristine, in the absence of pola administration in similar patient populations [19, 48]. This evidence concerns the gene POLA1 and peripheral neuropathy.